Eric Blanchard

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

Cooley advised Xometry, the global artificial intelligence-powered marketplace connecting buyers with suppliers of manufacturing services, on its $250 million aggregate principal amount of 0.75% convertible senior notes due 2030, which includes the initial purchasers’ option to purchase up to an additional $25 million aggregate principal amount of notes.

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, top technology, operational excellence and deep product knowledge to power movement from Point A to Point B, on its offering of $1 billion principal amount of 0% exchangeable senior notes due 2028.

Cooley advised Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, on its $625 million aggregate principal of 0.00% convertible senior notes due 2031, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes.